In a recent study published in JAMA Network Open, researchers found people with psychiatric disorders, including schizophrenia and mood disorders, are less likely to test positive for COVID-19 but have increased COVID-19 mortality.
The study is from the University of Texas and was conducted by Antonio L. Teixeira, et al.
The team examined the odds of testing positive for and mortality from COVID-19 among and between patients with schizophrenia, mood disorders, anxiety disorders, and a reference group with no major psychiatric conditions.
A total of 2,535,098 unique individuals were included in the population studied, of whom 3,350 had schizophrenia, 26,610 had mood disorders, and 18,550 had anxiety disorders.
The researchers found that the rate of testing positive for COVID-19 in 2020 was much lower for the schizophrenia group and the mood disorder group than the anxiety disorder group, which was closer to the reference group (9.86% and 9.86% vs. 11.91%).
But compared with the reference group, patients with schizophrenia were nearly four times more likely to die from COVID-19.
The odds of mortality were also increased for the mood disorders COVID-19 group and anxiety disorders group.
The study’s findings suggest the need to foster recognition of pandemic risks on specific groups of patients with psychiatric conditions and may drive alternative approaches to COVID-19 disease testing and interventions to improve clinical outcomes
If you care about COVID, please read studies that COVID-19 infection, more likely than vaccines, to cause heart inflammation, and new finding may lead to a longer-lasting COVID vaccine.
For more information about health, please see recent studies about nasal vaccine that could help fight new viral variants, and results showing this drug could help lower obesity, fatty liver, improve your heart health.
Copyright © 2022 Knowridge Science Report. All rights reserved.
